Use of collagen-polyvinylpirrolidone in the treatment of Parry-Romberg syndrome
Main Article Content
Keywords
Facial hemiatrophy, Collagen, Povidone-iodine
Abstract
Background: Parry-Romberg syndrome is characterized by the presence of progressive hemifacial atrophy that affects the growth and development of structures on one side of the face. Our objective was to introduce collagen-polyvinylpirrolidone as a new therapeutic option for Parry-Romberg syndrome in two clinical cases.
Clinical cases: two women, aging 56 and 28 years old, with facial hypocrhomic lesions, and right and left fronto-malar sunken area respectively, treated with topic steroids + penicilamina, fat grafts and silicone implants without improvement. We used collagen-polyvinylpirrolidone and they showed improvement: after six months there were not clinical or esthetical complications.
Conclusions: collagen-polivinilpirrolidone could be a new therapeutic option for Parry-Romberg syndrome with good clinical and esthetical results. It is easy to apply and it has few side effects and without complications.
References
Waters MF, Bhidayasiri R, Shields WD. Favorable longitudinal outcome in a patient with Parry-Romberg syndrome. Acta Neurol Scand. 2005:112(3): 192-3.
Budrewicz S, Koszewicz M, Koziorowska-Gawron E, Szewczyk P, Podemski R, Slotwisńki K. Parry-Romberg syndrome: clinical, elctrophysiological and neuroimaging correlations. Neurol Sci. 2012;33(2):423-7.
Okumura A, Ikuta T, Tsuji T, Kato T, Fukatsu H, Nagagawa S, et al. Parry-Romberg syndrome with a clinically silent white matter lesion. AJNR Am J Neuroradiol. 2006;27(8):1729-31.
Castañeda-Reyna MA, Galarza-Manyari C. Síndrome de Parry-Romberg asociado a epilepsia refractaria, atrofia de la duramadre y leucoencefalopatía quística cerebral. Rev Neurol. 2003;37(10):941-5.
Gonul M, Dogan B, Izci Y, Varol G. Parry-Romberg syndrome in association with anti-dsDNA antibodies: a case report. J Eur Acad Dermatol Venereol. 2005;19(6):740-2.
Ruffatti A, Peserico A, Rondinone R, Calligaro A, Del-Ross T, Ghirardello A, et al. Prevalence and characteristics of ant-single-stranded DNA antibodies in localized scleroderma. Comparison with systemic lupus erythematosus. Arch Dermatol. 1991;12 7(8):1180-3.
Honda-Fujimura SA, Galván-Esquivel V, Montes de Oca F, Ysita-Morales A. Calcitriol oral en el tratamiento de la esclerodermia localizada. Educ Invest Clin. 2000;1(2):92-6.
Berenguer B, Gallo H, Rodríguez-Urcelay P, Marín-Guztke M, González-Meli B, Enríquez-de Salamanca J. Trasplante libre de grasa para tratamiento de la enfermedad de Parry-Romberg infantil. Cir Pediatr. 2005;18(1):49-51.
Furuzawa-Carballeda CZ, García-Aranda RL, Furuzawa-Carballeda J. Estudio piloto sobre la eficacia del uso de la colágena-polivinilpirrolidona (clg-PVP) en la regeneración ósea en cirugía endodóncica. Rev Odontol Mex. 2005;9(4):191-6.
Furuzaawa-Carballeda J, Rojas E, Valverde M, Castillo I, Díaz de León L, Krötzsch E. Cellular and humoral responses to collagen-polyvinylpyrrolidone administered during short and long periods in humans. Can J Physiol Pharmacol. 2003;81(11): 1029-35.
Furuzawa-Carballeda J, Krötzsch E, Barilé-Fabris L, Alcalá M, Espinosa-Morales R. Subcutaneous administration of collagen-polyvinylpyrrolidone down regulates IL-1β, TNF-α, TGF-β1, ELAM-1 and VCAM-1 expression in scleroderma skin lesions. Clin Exp Dermatol. 2005;30(1):83-6.
Sikes PJ. Application of microvascular surgery to plastic surgery. J R Soc Med. 1980;73(1):55-9.